News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

HCC Related to Nonalcoholic Fatty Liver Disease Vs Other Causes Linked With Lower Rates of Cirrhosis, Surveillance

Jun 23, 2022
Hayley Virgil

Individuals with nonalcoholic fatty liver disease–related hepatocellular carcinoma were found to have lower rates of surveillance vs other potential causes of disease.

Lower surveillance rates and cirrhosis prevalence were identified in patients with nonalcoholic fatty liver disease (NAFLD)–related hepatocellular carcinoma (HCC) compared with other potential disease causes, according to findings from a systematic review and meta-analysis published in Lancet Oncology.

Investigators noted that fewer patients with NAFLD-related HCC received surveillance at 32.8% (95% CI, 12.0%-63.7%) compared with 55.7% (95% CI, 24.0%-83.3%) in patients with HCC secondary to other causes (P <.0001). Between the 2 groups, there were no significant differences in treatment allocation, including curative therapy, palliative therapy, and best supportive care. Although there were no differences in overall survival between the 2 groups (HR, 1.05; 95% CI, 0.92-1.20; P = .43), patients with NAFLD-related HCC had a longer disease-free survival compared with patients whose disease was tied to other causes (HR, 0.79; 95% CI, 0.63-0.99; P = .044).

“This study provides high-level evidence that a substantially higher proportion of patients with NAFLD-related hepatocellular carcinoma do not have cirrhosis and have lower surveillance rates than patients with hepatocellular carcinoma due to other causes. The proportion of hepatocellular carcinoma secondary to NAFLD is rising globally, and urgent measures are required to tackle the metabolic risk factors associated with NAFLD-related hepatocellular carcinoma. Further studies are required to improve hepatocellular carcinoma surveillance strategies for patients with NAFLD who are at high-risk of hepatocellular carcinoma without cirrhosis,” the investigators wrote.

Investigators initially identified 3631 potential articles for review, of which 61 were included in the final analysis following screening. These studies included 94,636 patients, of whom 15,377 had NAFLD-related disease and 79,259 had disease related to other causes.

The study’s primary outcomes were proportion of HCC secondary to NAFLD globally; comparison of patient and tumor characteristics between groups; and comparison of surveillance, treatment allocation, and survival outcomes between groups.

Patients had a median age of 67.8 years. Most patients with NAFLD-related HCC were located in South-East Asia, the Western Pacific, Europe, and the Americas. Investigators noted an increase in disease secondary to NAFLD from before the year 2000 (9.77%; 95% CI, 7.33%-12.92%) to 2010 and beyond (16.97%; 95% CI, 12.17%-23.16%; P = .045).

Patients in the NAFLD cohort were found to be older (mean difference, 5.62 years; 95% CI, 4.63-6.61; P <.0001) and had a higher body mass index (mean difference, 2.99 kg/m2; 95% CI, 2.20-3.78; P <.0001) than the comparator arm. Compared with individuals whose HCC was due to other causes, the NAFLD arm was more likely to present with metabolic complications such as diabetes (OR, 4.31; 95% CI, 3.19-5.80; P <.0001), hypertension (OR, 2.84; 95% CI, 2.09-3.86; P <.0001), and hyperlipidemia (OR, 3.43; 95% CI, 2.39-4.95; P <.0001).

Notably, 38.5% (95% CI, 27.9%-50,2%) with NAFLD-related HCC did not have cirrhosis compared with 14.6% (95% CI, 8.7%-23.4%; P <.0001) for all other causes. Broken down further, HCC without cirrhosis occurred in 21.7% of those with disease related to hepatitis B, 6.4% to hepatitis C, and 9.1% with alcohol. Compared with those whose disease was related to other causes, those with NAFLD-related disease had a greater tumor diameter (mean difference, 0.67 cm; 95% CI, 0.35-0.98; P = .0087) and were more likely to have unimodular lesions (OR, 1.36; 95% CI, 1.19-1.56; P = .0003).

Additional findings from the analysis indicated that 65.0% of patients in the NAFLD arm were assigned to receive curative therapy and 42.1% received palliative therapy. Moreover, 3.9% of patients in this group underwent liver transplant, 33.6% underwent resection, and 12.0% received ablation.

Reference

Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):P521-530. doi:10.1016/S1470-2045(22)00078-X

Related Videos
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
The combination of tremelimumab plus durvalumab improved survival for patients with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial.
Ghassan K. Abou-Alfa, MD, examined the trial design of the phase 3 HIMALAYA trial of tremelimumab plus durvalumab for frontline hepatocellular carcinoma, with results presented at the 2022 Gastrointestinal Cancers Symposium.
Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.
Related Content

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

January 18th 2017

ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers

May 24th 2023

GEN-001/Avelumab Elicits Positive Responses in Advanced Gastric/GEJ Cancer

May 22nd 2023

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

April 27th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

January 18th 2017

ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers

May 24th 2023

GEN-001/Avelumab Elicits Positive Responses in Advanced Gastric/GEJ Cancer

May 22nd 2023

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

April 27th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

January 18th 2017

ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers

May 24th 2023

GEN-001/Avelumab Elicits Positive Responses in Advanced Gastric/GEJ Cancer

May 22nd 2023

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

April 27th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023
Related Content

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023
Article

Patients with unresectable hepatocellular carcinoma receiving single tremelimumab regular interval durvalumab have a feasible immune-related adverse effect profile.


Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.


Claudin 18.2–targeting antibody-drug conjugate ATG-022 is under assessment as part of the phase 1 CLINCH study in patients with advanced or metastatic solid malignancies.

ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers

May 24th 2023
Article

Claudin 18.2–targeting antibody-drug conjugate ATG-022 is under assessment as part of the phase 1 CLINCH study in patients with advanced or metastatic solid malignancies.


Investigators indicate that GEN-001 and avelumab does not have safety concerns in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

GEN-001/Avelumab Elicits Positive Responses in Advanced Gastric/GEJ Cancer

May 22nd 2023
Article

Investigators say that they do not have any safety concerns regarding GEN-001 and avelumab in patients with advanced gastric or gastroesophageal junction adenocarcinoma.


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

April 27th 2023
Article

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.


Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma may experience significant survival benefit following treatment with zolbetuximab.

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023
Article

Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma may experience significant survival benefit following treatment with zolbetuximab.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.